Back to top
more

MeiraGTx (MGTX)

(Delayed Data from NSDQ)

$5.81 USD

5.81
407,797

+0.27 (4.87%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $5.81 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

MGTX Stock Up on Upbeat Efficacy Data From Parkinson's Disease Study

by Zacks Equity Research

MeiraGTx stock rises 15% as gene therapy candidate betters sham treatment in Parkinson's disease patients.

MeiraGTx (MGTX) Surges 14.9%: Is This an Indication of Further Gains?

by Zacks Equity Research

MeiraGTx (MGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Harmony Biosciences (HRMY) Surges 6.7%: Is This an Indication of Further Gains?

by Zacks Equity Research

Harmony Biosciences (HRMY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

MeiraGTx (MGTX) delivered earnings and revenue surprises of -145.16% and 98.28%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Arbutus Biopharma (ABUS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Arbutus (ABUS) delivered earnings and revenue surprises of -10% and 12.08%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of 12.27% and 93.94%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

MeiraGTx Holdings PLC (MGTX) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of -2.17% and 79.86%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Praxis Precision Medicines, Inc. (PRAX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Praxis Precision Medicines, Inc. (PRAX) delivered earnings and revenue surprises of 5.71% and 71.67%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Lifecore Biomedical (LFCR): Can Its 16.0% Jump Turn into More Strength?

by Zacks Equity Research

Lifecore Biomedical (LFCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Wall Street Analysts Think MeiraGTx Holdings PLC (MGTX) Could Surge 217.92%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 217.9% in MeiraGTx Holdings PLC (MGTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

MeiraGTx (MGTX): Strong Industry, Solid Earnings Estimate Revisions

by Zacks Equity Research

MeiraGTx (MGTX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

MeiraGTx (MGTX) Stock Surges 35% in a Month: Here's Why

by Zacks Equity Research

MeiraGTx's (MGTX) shares surge on the sale of rights for a rare ocular disease gene therapy for up to $ 415 million. This funding helps MGTX extend its cash runway into mid-2026.

Wall Street Analysts Believe MeiraGTx Holdings PLC (MGTX) Could Rally 221.78%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 221.8% in MeiraGTx Holdings PLC (MGTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of 10.17% and 44.08%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Guardant Health (GH) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Guardant Health (GH) delivered earnings and revenue surprises of 46.40% and 6.51%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Stoke Therapeutics, Inc. (STOK) Moves 7.7% Higher: Will This Strength Last?

by Zacks Equity Research

Stoke Therapeutics, Inc. (STOK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

MeiraGTx Holdings PLC (MGTX) Soars 8.2%: Is Further Upside Left in the Stock?

by Zacks Equity Research

MeiraGTx Holdings PLC (MGTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Does MeiraGTx Holdings PLC (MGTX) Have the Potential to Rally 320.9% as Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at a 320.9% upside potential for MeiraGTx Holdings PLC (MGTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Predict a 314.29% Upside in MeiraGTx Holdings PLC (MGTX): Here's What You Should Know

by Zacks Equity Research

The consensus price target hints at a 314.3% upside potential for MeiraGTx Holdings PLC (MGTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Icosavax, Inc. (ICVX) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Icosavax, Inc. (ICVX) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Xenon Pharmaceuticals (XENE) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of -1.61% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Certara, Inc. (CERT) Matches Q1 Earnings Estimates

by Zacks Equity Research

Certara, Inc. (CERT) delivered earnings and revenue surprises of 0% and 1.14%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of -66% and 66.81%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of -31.03% and 14.70%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Epizyme (EPZM) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Epizyme (EPZM) delivered earnings and revenue surprises of 41.67% and 172.20%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?